Michigan Attorney General Dana Nessel is launching an investigation into a drug company that manufactures insulin in the U.S. in an effort to better understand what drives the medication’s high cost.

ANN ARBOR – Michigan Medicine has partnered with type 1 diabetes research nonprofit JDRF to establish the new JDRF Center of Excellence at the University of Michigan. The goal of the center, through U-M’s Elizabeth Weiser Caswell Diabetes Institute, is to accelerate research to cure type 1 diabetes and to improve lives. Ann Arbor resident Elizabeth Weiser Caswell and her father, Regent Ron Weiser, have made leadership gifts to kickstart the project. “Michigan Medicine is the ideal partner for JDRF,” Caswell said in a news release. “The JDRF Center of Excellence and the Elizabeth Weiser Caswell Diabetes Institute establishes us as one of the premier diabetes centers in the country—and the strongest in the Midwest,” Thomas Gardner, principal investigator of the JDRF Center of Excellence and EWCDI, said in a news release.

From 1997 to 2016, insulin prices rose from about $20 per vial to over $250 per vial, according to a report from the Washington Post. The high prices have forced some people with diabetes to use expired insulin, rely on crowdfunding, or taking less insulin than they need in order to ration their supplies. Since 2017, at least 10 Americans have died from having to ration their insulin, according to the Right Care Alliance. WHO aims to duplicate HIV drug successThe process the WHO is undertaking is known as prequalification. Several presidential candidates have been outspoken in their calls for lower drug prices.